DelveInsight's “Smoking Cessation and Nicotine Addiction Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Smoking Cessation and Nicotine Addiction, historical and forecasted epidemiology as well as the Smoking Cessation and Nicotine Addiction market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the Smoking Cessation and Nicotine Addiction Market with DelveInsight's In-Depth Report @ Smoking Cessation and Nicotine Addiction Market Size
Key Takeaways from the Smoking Cessation and Nicotine Addiction Market Report
- According to DelveInsight estimates, EU4 and the UK accounted for approximately 63,953 thousand cases, which was the highest prevalent cases of tobacco use, followed by the US with around 50,886 thousand cases, and Japan with around 20,185 thousand cases in 2023. These cases are expected to decrease in the US, EU4 the UK, and Japan by 2034.
- Among the EU4 and the UK, Germany had the highest prevalent cases of tobacco use (approximately 18,101 thousand cases), followed by France (approximately 16,429 thousand cases) in 2023. On the other hand, the UK (8,788 thousand cases) had the lowest prevalent cases of tobacco use in EU4 and the UK countries and the 7MM.
- Tobacco use has been identified as male-dominant; in our analysis, the number of males suffering was higher than females. In 2023, ~59% of prevalent cases tobacco use of were of males, while ~41% of cases were of females in the 7MM.
- The leading Smoking Cessation and Nicotine Addiction Companies such as Achieve LifeSciences, NFL Biosciences SAS, Embera Neuro Therapeutics Inc., Axsome Therapeutics, Currax Pharmaceuticals LLC, Omeros Corporation, Promentis Pharmaceuticals, Otsuka Pharmaceutical, and others.
- Promising Smoking Cessation and Nicotine Addiction Pipeline Therapies such as NicVAX vaccine, Varinecline (Chantix), Cytisine, Nicotine Replacement Therapy (NRT), Liraglutide, Bupropion, and others.
Stay ahead in the Smoking Cessation and Nicotine Addiction Therapeutics Market with DelveInsight’s Strategic Report @ Smoking Cessation and Nicotine Addiction Market Outlook
Smoking Cessation and Nicotine Addiction Epidemiology Segmentation in the 7MM
- Prevalent Cases of Tobacco Use
- Gender-specific Prevalent Cases of Tobacco Use
- Age-specific Prevalent Cases of Tobacco Use
- Prevalent Cases of Tobacco Use by Product Type
- Prevalent Nicotine Dependent Cases Among Cigarette Smokers
- Prevalent Cases of Smoking Cessation
Download the report to understand which factors are driving Smoking Cessation and Nicotine Addiction Epidemiology trends @ Smoking Cessation and Nicotine Addiction Prevalence
Smoking Cessation and Nicotine Addiction Marketed Drugs
- CHANTIX/ CHAMTIX (varenicline): Pfizer
CHANTIX, known chemically as varenicline tartrate, is a nicotinic receptor partial agonist used as an aid for smoking cessation. Unlike nicotine replacement therapies, CHANTIX works by blocking the pleasurable effects of smoking and reducing cravings and withdrawal symptoms. The US FDA approved varenicline in May 2006 as the first oral non-nicotine smoking cessation treatment. It has also been approved in the EU4, the UK, and Japan for the same purpose. In May 2007, Pfizer announced that NICE recommended CHAMTIX (varenicline) for use in the UK's National Health Service for adult smokers wishing to quit. In August 2021, the FDA approved the first generic version of CHANTIX, developed by Par Pharmaceutical, offering 0.5 mg and 1 mg tablets. This milestone provides a more accessible option for individuals seeking to overcome nicotine addiction.
- ZYBAN (bupropion): GlaxoSmithKline
ZYBAN (bupropion hydrochloride) sustained-release tablets are a non-nicotine aid for smoking cessation. Chemically unrelated to nicotine or other treatments for nicotine addiction, ZYBAN was initially developed as an antidepressant under the names WELLBUTRIN and WELLBUTRIN SR. Bupropion is a selective inhibitor of the neuronal reuptake of catecholamines (noradrenaline and dopamine) with minimal effect on serotonin reuptake, and it does not inhibit monoamine oxidase. The precise mechanism by which ZYBAN aids in smoking cessation is unclear but is believed to involve noradrenergic and/or dopaminergic pathways. Initially introduced in 1989 as an antidepressant, bupropion was later produced in a sustained-release (SR) formulation in 1996. Its smoking cessation properties were identified in 1997, leading to its recognition as a first-line anti-smoking agent in the US and UK. In May 2010, Mylan Pharmaceuticals received FDA approval for a generic version of ZYBAN, providing a cost-effective option for those seeking to quit smoking.
Smoking Cessation and Nicotine Addiction Emerging Drugs
- Cytisinicline (cytisine): Achieve Life Sciences
Cytisinicline (cytisine) is an oral, plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment approved and marketed in Central and Eastern Europe for over 20 years. Cytisinicline has completed a Phase III study, evaluating the efficacy and safety of 3 mg cytisinicline thrice a day for a treatment duration of 42 days/6 weeks in adult smokers cytisinicline. In addition to this trial, the company is conducting another Phase III study, ORCA-OL, which is in progress as per the company’s pipeline. Achieve Life Sciences is also evaluating cytisinicline in Phase II for the e-cigarette user population.
- NFL-101: NFL Biosciences SAS
NFL-101, a patented botanical drug candidate, aims to improve smoking cessation rates. It involves two subcutaneous injections one week apart, with optional injections at three and six months if needed. A Phase I/II trial confirmed its safety and efficacy for long-term cessation without compensatory smoking. Unlike varenicline (Chantix/Champix) and nicotine replacement therapies, NFL-101 contains minimal nicotine and is derived from natural tobacco leaf proteins. In February 2023, NFL Biosciences collaborated with the CEA to study NFL-101's mechanism using molecular imaging. In November 2021, they partnered with Diverchim to develop GMP-compliant active ingredients for NFL-101 and NFL-201 for treating tobacco and cannabis addiction. This supports the production of essential components for the CESTO II (Phase II/III) clinical study. Results from the Phase IIb efficacy study (CESTO 2) are expected in July 2024.
- EMB-001: Embera NeuroTherapeutics, Inc.
EMB-001, a patented combination of metyrapone and oxazepam, targets the stress response system to address addiction and relapse by reducing stress-induced cravings and loss of control. It aims to maximize efficacy by affecting multiple pathways and promoting long-term abstinence across various addictions. In 2019, Embera NeuroTherapeutics received substantial grants to advance EMB-001 into Phase II clinical studies for cocaine use disorder and smoking cessation. The National Institute on Drug Abuse (NIDA) provided part of a USD 11.1 million grant for a Phase II study on cocaine use disorder, while the Rose Research Center (RRC) in North Carolina received funding to evaluate EMB-001 for smoking cessation, supported by the Foundation for a Smoke-Free World. In the nicotine study, EMB-001 also demonstrated a statistically significantly greater effect relative to varenicline (CHANTIX), the clinical market leader for smoking cessation efficacy.
Get In-Depth Knowledge on Smoking Cessation and Nicotine Addiction Market Trends and Forecasts with DelveInsight @ Smoking Cessation and Nicotine Addiction Treatment Market
Smoking Cessation and Nicotine Addiction Market Outlook
There are effective treatments that support tobacco cessation, including both behavioral therapies and FDA-approved medications. Several distinct products and services are available today for smoking cessation, alongside smoking alternatives that are not specifically indicated for cessation. FDA-approved pharmacotherapies include various forms of nicotine replacement therapies (NRTs) in the form of transdermal patches, gums, nasal sprays, oral inhalers, and lozenges.
Scope of the Smoking Cessation and Nicotine Addiction Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Smoking Cessation and Nicotine Addiction Companies- Achieve LifeSciences, NFL Biosciences SAS, Embera Neuro Therapeutics Inc., Axsome Therapeutics, Currax Pharmaceuticals LLC, Omeros Corporation, Promentis Pharmaceuticals, Otsuka Pharmaceutical, and others.
- Smoking Cessation and Nicotine Addiction Pipeline Therapies- NicVAX vaccine, Varinecline (Chantix), Cytisine, Nicotine Replacement Therapy (NRT), Liraglutide, Bupropion, and others.
- Smoking Cessation and Nicotine Addiction Therapeutic Assessment: Smoking Cessation and Nicotine Addiction current marketed and Smoking Cessation and Nicotine Addiction emerging therapies
- Smoking Cessation and Nicotine Addiction Market Dynamics: Smoking Cessation and Nicotine Addiction market drivers and Smoking Cessation and Nicotine Addiction market barriers
- Smoking Cessation and Nicotine Addiction Unmet Needs, KOL’s views, Analyst’s views, Smoking Cessation and Nicotine Addiction Market Access and Reimbursement
Unlock Strategic Insights with DelveInsight’s Comprehensive Smoking Cessation and Nicotine Addiction Market Report @ Smoking Cessation and Nicotine Addiction Market Drivers and Barriers
Table of Content
1 Key Insights
2 Report Introduction
3 Smoking Cessation and Nicotine Addiction Market Overview at a Glance
4 Epidemiology and Market Forecast Methodology
5 Key Events
6 Executive Summary of Smoking Cessation and Nicotine Addiction
7 Smoking Cessation and Nicotine Addiction: Disease Background and Overview
8 Epidemiology and Patient Population of Smoking Cessation and Nicotine Addiction
9 Patient Journey
10 Marketed Drugs
11 Emerging Drugs
12 Smoking Cessation and Nicotine Addiction: Seven Major Market Analysis
13. Market Size of Smoking Cessation and Nicotine Addiction in Japan
14 Key Opinion Leaders’ View
15 SWOT Analysis
16 Unmet needs
17 Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
